Oral Answers to Questions

Stephen Metcalfe Excerpts
Wednesday 3rd May 2023

(12 months ago)

Commons Chamber
Read Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
George Freeman Portrait George Freeman
- View Speech - Hansard - - - Excerpts

Here we go—Labour talking Britain down again. The truth is that I am not at all complacent about the clinical trials numbers. At the Life Sciences Council, in the next few weeks, we will be setting out a very clear plan to reverse the decline since the pandemic in the NHS.

The hon. Lady might have mentioned the major investment coming into west London—her part of the world—including the MedTech SuperConnector, the spin-outs there and SynbiCITE, the synthetic biology hub. She might at least acknowledge the major investment —billions of pounds—from Moderna and BioNTech into this country, laying the foundation for a next phase of science innovation. With the life sciences sector, we are in a global race, but we are still leading in the technologies of tomorrow.

Stephen Metcalfe Portrait Stephen Metcalfe (South Basildon and East Thurrock) (Con)
- View Speech - Hansard - -

Can my hon. Friend comment on the Department’s 10-point science and technology framework, which will help provide the long-term funding needed to turn the start-ups he has mentioned into sustainable, successful, globally leading businesses?

George Freeman Portrait George Freeman
- View Speech - Hansard - - - Excerpts

I thank my hon. Friend, who has been a strong champion of that agenda. In the new Department’s science and technology framework we have set out a long-term, 10-year view of the serious reforms that we need to make to procurement, regulation and skills across the whole of Government if we are to drive our science superpower agenda. A fundamental part of that is converting the health of our start-up ecosystem into scale-ups. That is why the Treasury is leading on the re-regulation of pension funds—so that we can unlock some of our pension trillions and put it into supporting our companies to grow here rather than go to NASDAQ.